Last updated: June 6, 2026
ALTAVERA drug suppliers: who manufactures, supplies, and supplies-to-NDA batches in the supply chain
Executive summary: Sufficient, citable information is not available to identify specific suppliers/manufacturers for ALTAVERA (active ingredient, dosage form, NDA/BLA, labeler, contract manufacturing site, or Orange Book/DSCSA data). Without a verifiable drug identity (e.g., generic name, strength, dosage form, and regulatory application), any named “suppliers” would be speculative.
What is ALTAVERA and who is the manufacturer listed on the label?
Featured snippet answer: ALTAVERA’s labeler/manufacturer identity cannot be determined from the provided input.
What NDA/BLA labeler details identify ALTAVERA’s supply-chain owner?
- NDA/BLA number
- Applicant/holder
- Labeler name on the container label
- Dosage form and strength
- Route of administration
How does DSCSA labeling distinguish “labeler” vs “manufacturer of record”?
- Labeler (directing entity for distribution)
- Manufacturer of record (commercial batch release party)
- Site of manufacture (manufacturing facility)
Which companies are ALTAVERA’s API suppliers and where is the API made?
Featured snippet answer: API supplier and API manufacturing sites cannot be identified without the active ingredient and strength.
What documents usually list ALTAVERA API suppliers?
- FDA Drug Master File (DMF) references tied to the NDA/BLA
- Supplier declarations in CMC sections
- Inspection outcomes tied to the manufacturing site
Which API supply-chain roles matter for patent and litigation risk?
- API synthesis intermediate suppliers
- Final API crystallization/polishing vendors
- Sterile fill-finish versus non-sterile drug substance manufacturing
What contract manufacturers (CMOs/CDMOs) supply ALTAVERA finished dosage forms?
Featured snippet answer: CMO/CDMO manufacturers cannot be identified from the provided input.
How do you map CMO sites to ALTAVERA manufacturing batches?
- Site listings in the FDA application
- Facility registration and product listing (if identifiable)
- Inspection history and Warning Letters (if any)
What manufacturing steps constrain ALTAVERA supply?
- Solid oral manufacturing vs sterile injectables
- Blending/granulation/compression and coating
- Sterile filtration, aseptic processing, lyophilization (if applicable)
What does the Orange Book list for ALTAVERA, and who are the listed assignees?
Featured snippet answer: Orange Book listings cannot be generated because ALTAVERA’s drug identity (NDC/NDA) is not provided.
How Orange Book listings connect to real suppliers
- Listed drug applications map to product-level labeler/sponsor
- Patent assignees indicate ownership but not necessarily manufacturing
- Use of listed certifications ties into distribution status
When does ALTAVERA lose exclusivity and what supplier shifts happen before launch by generics/biosimilars?
Featured snippet answer: Exclusivity and timeline cannot be determined without knowing the active ingredient and reference listed drug.
What exclusivity types would affect ALTAVERA supply strategy?
- New chemical entity (NCE) exclusivity
- Orphan drug exclusivity
- Pediatric exclusivity
- 505(b)(2) or switch-related protections
Are there Paragraph IV challenges for ALTAVERA, and which generic entrants are targeting it?
Featured snippet answer: Paragraph IV status cannot be determined without the FDA product identity.
How to connect challenges to supplier risk
- Settlements can lock certain manufacturers from launching
- Licensed entrants often require CMO or API sourcing changes
What formulations are protected for ALTAVERA, and does that constrain which suppliers can make it?
Featured snippet answer: Formulation IP coverage cannot be assessed without the ALTAVERA composition and patent listings.
Common formulation-IP categories that affect supply
- Tablet coating compositions
- Extended-release matrix/polymers
- Particle size distribution and polymorph control
- Bioequivalence-driven formulation lock
How does ALTAVERA compare with competing brands on the supplier landscape?
Featured snippet answer: Competitor comparison cannot be done without the active ingredient and strength.
What comparison reveals for procurement
- Alternate CMOs already qualified by generic entrants
- Shared API suppliers across competitors
- Regional manufacturing footprints
Key Takeaways
- ALTAVERA supplier identification requires verifiable drug identity (active ingredient, dosage form, strength, and FDA application identifiers).
- Labeler, API supplier, CMO/CDMO, and site-of-manufacture cannot be stated from the provided information without generating unverified claims.
FAQs
- How do I find the labeler and manufacturer of ALTAVERA on FDA/NDC records?
- How can I identify ALTAVERA API manufacturers from DMF references?
- Which FDA facility registrations typically reveal who manufactures ALTAVERA drug product?
- Where do Orange Book listings show ALTAVERA patent assignees, and how does that map to suppliers?
- How do generic entrants’ launch dates change ALTAVERA’s contract manufacturing mix?
References
No sources were cited because the drug identity for “ALTAVERA” was not provided in a form that supports retrieval of authoritative manufacturer/supplier records.
